{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T10:49:10Z","timestamp":1783334950208,"version":"3.54.6"},"reference-count":33,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"AN2 Therapeutics Inc"},{"name":"HHS | National Institutes of Health","award":["NIH AI155664"],"award-info":[{"award-number":["NIH AI155664"]}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2024,8,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:sec>\n            <jats:title\/>\n            <jats:p>\n              <jats:italic>Mycobacteroides abscessus<\/jats:italic>\n              (\n              <jats:italic>Mab<\/jats:italic>\n              or\n              <jats:italic>Mycobacterium abscessus<\/jats:italic>\n              ) is a fast-growing mycobacterium that is ubiquitous in the environment and can cause opportunistic disease in people with lung comorbidity and immunodeficiency. There are no Food and Drug Administration-approved drugs for this disease, and repurposed antibiotics have a poor microbiological response. To address the need for effective new antibiotics, we determined the efficacy of epetraborole (EBO) against three\n              <jats:italic>Mab<\/jats:italic>\n              clinical isolates in a mouse model of lung\n              <jats:italic>Mab<\/jats:italic>\n              infection. Reduction in lung\n              <jats:italic>Mab<\/jats:italic>\n              burden over 4 weeks of treatment was the study end point. EBO was administered orally once daily at doses of 25 and 50 mg\/kg, which achieved exposures approximating the once-daily dosing of 250 mg and 500 mg, respectively, in humans. EBO administration led to a gradual reduction in the lung\n              <jats:italic>Mab<\/jats:italic>\n              burden. After 4 weeks of treatment, the efficacies of 25 and 50 mg\/kg EBO against isolates ATCC 19977 and M9501 were comparable. However, against isolate M9530, 50 mg\/kg EBO was more efficacious than 25 mg\/kg and comparable with parenteral imipenem, one of the most efficacious antibiotics against\n              <jats:italic>Mab<\/jats:italic>\n              . We also undertook a dose-ranging study by evaluating the efficacies of once-daily oral administration of 0.5, 5, 10, 25, and 100 mg\/kg EBO against M9501 over 4 weeks. Once-daily oral 100 mg\/kg EBO was as effective as twice-daily 100 mg\/kg imipenem injection. Our study suggests that EBO could address the unmet need for effective oral treatment options for\n              <jats:italic>Mab<\/jats:italic>\n              lung disease, given the high rates of\n              <jats:italic>Mab<\/jats:italic>\n              drug resistance and limited tolerable intravenous options.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1128\/aac.00648-24","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T13:00:49Z","timestamp":1721221249000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy of epetraborole against\n            <i>Mycobacteroides abscessus<\/i>\n            in a mouse model of lung infection"],"prefix":"10.1128","volume":"68","author":[{"given":"Binayak","family":"Rimal","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher K.","family":"Lippincott","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA"},{"name":"Center for Nontuberculous Mycobacteria and Bronchiectasis, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandra M.","family":"Panthi","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xie","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany R.","family":"Keepers","sequence":"additional","affiliation":[{"name":"AN2 Therapeutics, Inc., Menlo Park, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MRK","family":"Alley","sequence":"additional","affiliation":[{"name":"AN2 Therapeutics, Inc., Menlo Park, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2214-0114","authenticated-orcid":true,"given":"Gyanu","family":"Lamichhane","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA"},{"name":"Center for Nontuberculous Mycobacteria and Bronchiectasis, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-020-0331-1"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.10.055"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.07.035"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2021.11.007"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr578"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms7030090"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1142189"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01339-16"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02058-12"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115936"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009965"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad500.134"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01156-21"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-60452-1"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00614-19"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2022.102268"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01704-21"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00536-22"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/msphere.00665-22"},{"key":"e_1_3_4_21_2","volume-title":"Performance standards for susceptibility testing of mycobacteria, nocardia spp., and other aerobic actinomycetes","author":"CLSI","year":"2023","unstructured":"CLSI. 2023. Performance standards for susceptibility testing of mycobacteria, nocardia spp., and other aerobic actinomycetes. 2nd ed. CLSI M24S.","edition":"2"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/jid.1953.18"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02545-20"},{"key":"e_1_3_4_24_2","volume-title":"ID week. Washington DC","author":"Eckburg PB","year":"2022","unstructured":"Eckburg PB, Clarke D, Long J, Chanda S, Krause KM, Easom EE, Talbot G, Rubino C, Molga A. 2022. Tolerability and pharmacokinetics of oral epetraborole at the predicted therapeutic dosage for Mycobacterium avium complex (MAC) lung disease: a phase 1b dose-ranging and food effect study. In ID week. Washington DC"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2017.04.166"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/9781555819316"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01066-13"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0092-8674(01)00286-0"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio884"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/30.2.129"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2017.0286"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.67.9.4700-4707.1999"},{"key":"e_1_3_4_33_2","first-page":"313","volume-title":"Molecular genetics of mycobacteria","author":"Larsen M","year":"2000","unstructured":"Larsen M. 2000. Some common methods in mycobacterial genetics, p 313\u2013320. In Hatfull GF, Jacobs WR J (ed), Molecular genetics of mycobacteria. American Society for Microbiology, Washington DC."},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/am.26.5.658-665.1973"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00648-24","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00648-24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T13:03:14Z","timestamp":1723035794000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.00648-24"}},"subtitle":[],"editor":[{"given":"Sean","family":"Wasserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,8,7]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8,7]]}},"alternative-id":["10.1128\/aac.00648-24"],"URL":"https:\/\/doi.org\/10.1128\/aac.00648-24","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,7]]},"assertion":[{"value":"2024-04-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00648-24"}}